Cargando…
Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
Edema Factor (EF) is a component of Bacillus anthracis toxin essential for virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, nucleotides and/or ions, have been extensively characterize...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446745/ https://www.ncbi.nlm.nih.gov/pubmed/23012649 http://dx.doi.org/10.3390/toxins4080580 |
_version_ | 1782244013556891648 |
---|---|
author | Laine, Élodie Martínez, Leandro Ladant, Daniel Malliavin, Thérèse Blondel, Arnaud |
author_facet | Laine, Élodie Martínez, Leandro Ladant, Daniel Malliavin, Thérèse Blondel, Arnaud |
author_sort | Laine, Élodie |
collection | PubMed |
description | Edema Factor (EF) is a component of Bacillus anthracis toxin essential for virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, nucleotides and/or ions, have been extensively characterized by X-ray crystallography. Those structural data allowed molecular simulations analysis of various aspects of EF action mechanism, including the delineation of EF and CaM domains through their association energetics, the impact of calcium binding on CaM, and the role of catalytic site ions. Furthermore, a transition path connecting the free inactive form to the CaM-complexed active form of EF was built to model the activation mechanism in an attempt to define an inhibition strategy. The cavities at the surface of EF were determined for each path intermediate to identify potential sites where the binding of a ligand could block activation. A non-catalytic cavity (allosteric) was found to shrink rapidly at early stages of the path and was chosen to perform virtual screening. Amongst 18 compounds selected in silico and tested in an enzymatic assay, 6 thiophen ureidoacid derivatives formed a new family of EF allosteric inhibitors with IC50 as low as 2 micromolars. |
format | Online Article Text |
id | pubmed-3446745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-34467452012-09-25 Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors Laine, Élodie Martínez, Leandro Ladant, Daniel Malliavin, Thérèse Blondel, Arnaud Toxins (Basel) Review Edema Factor (EF) is a component of Bacillus anthracis toxin essential for virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, nucleotides and/or ions, have been extensively characterized by X-ray crystallography. Those structural data allowed molecular simulations analysis of various aspects of EF action mechanism, including the delineation of EF and CaM domains through their association energetics, the impact of calcium binding on CaM, and the role of catalytic site ions. Furthermore, a transition path connecting the free inactive form to the CaM-complexed active form of EF was built to model the activation mechanism in an attempt to define an inhibition strategy. The cavities at the surface of EF were determined for each path intermediate to identify potential sites where the binding of a ligand could block activation. A non-catalytic cavity (allosteric) was found to shrink rapidly at early stages of the path and was chosen to perform virtual screening. Amongst 18 compounds selected in silico and tested in an enzymatic assay, 6 thiophen ureidoacid derivatives formed a new family of EF allosteric inhibitors with IC50 as low as 2 micromolars. MDPI 2012-07-31 /pmc/articles/PMC3446745/ /pubmed/23012649 http://dx.doi.org/10.3390/toxins4080580 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Laine, Élodie Martínez, Leandro Ladant, Daniel Malliavin, Thérèse Blondel, Arnaud Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors |
title | Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors |
title_full | Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors |
title_fullStr | Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors |
title_full_unstemmed | Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors |
title_short | Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors |
title_sort | molecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446745/ https://www.ncbi.nlm.nih.gov/pubmed/23012649 http://dx.doi.org/10.3390/toxins4080580 |
work_keys_str_mv | AT laineelodie molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors AT martinezleandro molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors AT ladantdaniel molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors AT malliavintherese molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors AT blondelarnaud molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors |